Profound Medical Corp T.PRN

Alternate Symbol(s): PROF

Healthcare Medical Devices

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

TSX:PRN - Post by User

Profound Medical Corp > analyst's review.

<< Previous

Bullboard Posts

Next >>

Comment by HomerAndCompanyon Nov 05, 2021 4:21pm

197 Views

Post# 34094127

RE:analyst's review.

Perhaps we could get a bounce without the dead cat?

If "we reiterate our Strong Buy" means anything this analyst (still) thinks PRN is the cat's meow. Something set the cat amongst the pigeons today. It wasn't pretty - that chart looks like something the cat dragged in. PRN blamed COVID - again. No doubt trying to get things done with COVID related disruptions is like hearding cats. But if anyone has reason to think that this cat is dead - I think it's time to let the cat out of the bag - and enlighted us.

ghayes wrote: I am keeping a close eye on the RSI .. possibly a dead cat bounce coming ?

Here's the first paragraph of RJ analyst's take on the latest activity of PROF.
sorry the formatting won't copy over.

RECOMMENDATION Profound Medical (PROF-NASDAQ, SB1) reported 3Q21 results last night with a wide miss on Rev. ($2.5 mln vs. $3.1 mln RJe; $3.5 mln consensus; see our Pre-3Q21 expectations).
So, with this Q’s disappointing revenue, we have taken a moment to reflect on our view of PROF. We have always believed the right way to think about this stock is on an 18-month time horizon, certainly not quarter-to-quarter; however, while our conviction in PROF’s fundamentals remain undiminished, we do owe a mea culpa on the fact that we got the timing of our call wrong by ~1 year(explanationonpg.2). As such, we take this opportunity to adjust our revenue estimates to what we believe is a reasonable baseline that PROF should meet—if not, beat—going forward. As such, we cut our 2022 EV/Rev.-driven target price to $28, but, maintaining our focus on PROF’s exceedingly strong fundamentals, we reiterate our Strong Buy ratin